Shortly after completing an acquisition of cryoablation and microwave ablation technologies, Varian expanded its portfolio of IOS technologies by acquiring the Embozene® and Oncozene® brand embolization microspheres products from Boston Scientific. These latest acquisitions mark another milestone in our commitment to growing the Varian IOS portfolio.
Varian has now named Francis R. Facchini, M.D., FSIR, as the company’s new chief medical officer for Interventional Oncology, reporting to Dee Khuntia, chief medical officer for Varian. Dr. Facchini has global responsibility for overseeing all aspects of this area including ongoing development of Varian's IO treatment offerings, clinical strategy, and helping advance the field of interventional oncology as an important pillar of patient care.
Dr. Facchini, who holds an MD from Loyola University and a BA in philosophy from DePauw University, was most recently chief medical officer and head of medical affairs for BTG Plc., where he had responsibility for developing and commercializing products targeting critical care, cancer, vascular and other disorders. He previously served as global director of Medical and Clinical Affairs for Angiodynamics, Inc. and was chief medical officer of Navilyst Medical, Inc.
"Frank is already making his mark; he is a great addition to the Varian Medical Affairs team," said Khuntia. "He is a strategic thinker with strong business acumen and a deep understanding of this ever-changing industry. As a key opinion leader in the field of Interventional Oncology, Frank has a proven track record delivering highly creative, impactful solutions that will benefit Varian in our fight against cancer."
Visit www.varian.com/ios for more information about Varian’s ablation and embolization products.